EXHIBIT 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED

FINANCIAL STATEMENTS

ASP Isotopes Inc. (the “Company” or “ASP Isotopes”) acquired the issued share capital of Renergen Limited, a public company incorporated under the laws of the Republic of South Africa (“Renergen”), on January 6, 2025 by issuing new shares of ASP Isotopes common stock to Renergen shareholders at the ratio of 0.09196 shares of ASP Isotopes common stock for each Renergen ordinary share, resulting in ASP Isotopes issuing 14,270,000 new shares of ASP Isotopes common stock to acquire the 155,170,891 Renergen ordinary shares, net of treasury shares, based on the shares in issue at January 2, 2025 (the record date). As a result of the transaction, Renergen became a direct, wholly owned subsidiary of the Company (the “Acquisition”).

The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X, Pro Forma Financial Information, as amended by the final rule, Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses”.

Release No. 33-10786 replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the transaction (“Transaction Accounting Adjustments”) and the option to present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (“Management’s Adjustments”). The Company has elected not to present Management’s Adjustments and has only presented Transaction Accounting Adjustments in the following unaudited pro forma condensed combined financial information.

The Company and Renergen have different fiscal year ends (December 31 and February 28 (or 29), respectively). As Renergen’s fiscal year end of February 28, 2025 is within one fiscal quarter of the Company’s fiscal year end of December 31, 2024, the pro forma condensed combined statement of income for the year ended December 31, 2024 includes Renergen’s operating results for its respective fiscal year ended February 28, 2025 as permitted by Rule 11-02(c)(3) of Regulation S-X, which allows the combination of financial information for companies if their fiscal years end within one fiscal quarter of each other. To comply with SEC rules and regulations for companies with different fiscal year ends, the pro forma condensed combined financial information has been prepared utilizing periods that differ by less than one fiscal quarter.

The unaudited pro forma condensed combined balance sheet is based on historical balance sheets of the Company and Renergen and has been prepared to reflect the acquisition as if it had been consummated on September 30, 2025. Due to different fiscal year ends, such pro forma information is based upon the historical consolidated balance sheet data of the Company as of September 30, 2025 and Renergen as of August 31, 2025. The pro forma combined statements of operations have been prepared to reflect the acquisition as if it had been consummated on January 1, 2024. The unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31, 2024 combines the Company’s historical consolidated statement of operations for the year then ended with Renergen’s historical consolidated statement of operations for the year ended February 28, 2025. The unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025 combines the Company’s historical consolidated statement of operations for the nine months then ended with Renergen’s historical consolidated statement of operations for the nine months ended August 31, 2025. Revenue and net loss of $0.8 million and $5.0 million, respectively, for Renergen’s three months ended February 28, 2025 is included in both the twelve month period and the nine month period pro forma condensed combined statements of operations.

The pro forma adjustments and allocation of purchase price are preliminary, are based on management’s current estimates of the fair value of the assets to be acquired and liabilities to be assumed, and are based on all available information.

As of the date of the Current Report on Form 8-K to which the following unaudited pro forma condensed combined financial statements are filed as an exhibit (the “Form 8-K”), the Company has not completed the detailed valuation analysis necessary to arrive at final estimates of the fair market value of the assets of Renergen to be acquired and the liabilities to be assumed and the related allocations of purchase price, nor has it identified all adjustments necessary to conform Renergen’s accounting policies to the Company’s accounting policies. Based on the information currently available, the Company has made certain adjustments to the historical book values of the assets and liabilities of Renergen to reflect preliminary estimates of fair values necessary to prepare the unaudited pro forma condensed combined financial information, with the excess of the purchase price over the adjusted historical net assets of Renergen recorded as goodwill. Actual results may differ from unaudited pro forma condensed combined financial information provided herein once the Company has determined the final purchase price for Renergen, has completed the valuation analysis necessary to finalize the required purchase price allocations and has identified any additional conforming accounting policy changes for Renergen. There can be no assurance that such finalization will not result in material changes.

1

Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial statements are described in the accompanying notes. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed. The unaudited pro forma condensed combined financial statements should be read in conjunction with the Company’s historical consolidated financial statements contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC and the historical combined financial statements of Renergen and accompanying notes filed as exhibits to the Form 8-K.

The following unaudited pro forma condensed combined financial statements gives effect to the Acquisition, which includes adjustments for the following:

	·	the conversion of Renergen’s historical financial statements from South African rand (ZAR) to U.S. Dollars using the period-end rate at August 31, 2025 of $0.0567 per ZAR for the unaudited condensed combined pro forma balance sheet and the weighted average of the monthly average rates during the nine months ended August 31, 2025 of $0.0549 per ZAR for the unaudited condensed combined pro forma statement of income;
	·	certain adjustments to reflect Renergen’s historical financial information on a U.S. GAAP basis;
	·	certain reclassifications to conform Renergen’s historical financial statement presentation to the Company’s presentation;
	·	the shares of the Company’s common stock to be issued in connection with the Acquisition, valued at $92.9 million as of January 6, 2026; and
	·	non-recurring transaction costs in connection with the Acquisition.

The estimated income tax rate applied to the pro forma adjustments is 21%. The estimated pro forma blended statutory rate, and all other tax amounts are stated at their historical amounts as the combined company’s overall effective tax rate has not yet been determined. The pro forma condensed combined provision for income taxes does not necessarily reflect the amounts that would have resulted had the Company and Renergen filed consolidated income tax returns for the periods presented.

Valuations of the Company’s intangible assets are expected to be finalized no later than one year from the date of acquisition. Any value assigned to these assets will represent a reclassification from the goodwill asset recorded in our preliminary purchase price allocation. Any reclassification recorded could result in further adjustments to pro forma combined financial statements, including but not limited to adjustments to amortization expense, deferred tax liabilities and income tax expense.

The following unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and are based on available information and assumptions that the Company believes are reasonable. They do not purport to represent what the actual consolidated results of operations or the consolidated financial position of the Company would have been had the Acquisition and related financing transactions occurred on the dates indicated, or on any other date, nor are they necessarily indicative of the Company’s future consolidated results of operations or consolidated financial position after the Acquisition and related financing transactions. The Company’s actual financial position and results of operations after the Acquisition will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified and changes in operating results of the Company and Renergen following the date of the unaudited pro forma condensed combined financial statements.

2

The unaudited pro forma condensed combined statement of operations does not include costs that may result from integration activities. The Company has not identified any Acquisition contingencies where the related asset, liability, or impairment is probable and the amount of the asset, liability or impairment can be reasonably estimated. Prior to the end of the purchase price allocation period, not to exceed one year from the acquisition date, if information becomes available that would indicate it is probable that such events have occurred and the amounts can be reasonably estimated, such items will be included in the purchase price.

This information should be read in conjunction with:

	·	accompanying notes to the unaudited pro forma condensed combined financial statements;
	·	separate unaudited historical consolidated financial statements of the Company as of and for the three and nine-month periods ended September 30, 2025 included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025;
	·	separate audited historical consolidated financial statements of the Company as of and for the fiscal year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024;
	·	separate audited historical financial statements of Renergen as of and for year ended February 28, 2025, previously filed with the SEC on the Company’s Current Report on Form 8-K; and
	·	separate unaudited historical financial statements of Renergen as of and for six-month period ended August 31, 2025, included elsewhere in this Form 8-K.

3

Unaudited Pro Forma Condensed Combined Balance Sheet

		ASP Isotopes Inc. September 30, 2025				Renergen August 31, 2025 Adjusted (Note 2)				ProForma Adjustments (Note 3)				Pro Forma
ASSETS:
Current assets:
Cash and cash equivalents		$	113,942,156			$	9,240,717			$	—			$	123,182,873
Accounts receivable			17,425,680				586,017				—				18,011,697
Inventory			1,371,738				56,046				—				1,427,784
Prepaid expenses and other current assets			10,099,525				1,381,314				—				11,480,839
Restricted cash			—				4,137,366				—				4,137,366
Lease receivable - current			16,733				394,871				—				411,604
Note receivable			31,189,144				—				(31,189,144	)(J)			—
Total current assets			174,044,976				15,796,331				(31,189,144	)			158,652,163
Property, plant and equipment, net			30,930,235				114,977,063				—				145,907,298
Operating lease right-of-use lease assets			971,658				513,650				—				1,485,308
Deferred tax assets			68,008				10,579,698				—				10,647,706
Goodwill			6,849,119				—				43,270,442	(A)			50,119,561
Other noncurrent assets			5,102,480				—				—				5,102,480
Intangible assets			1,190,562				6,435,928				—				7,626,490
Restricted cash			—				1,436,849				—				1,436,849
Lease receivable - noncurrent			410,223				1,928,115				—				2,338,338
Equity method investments			1,322,900				—				—				1,322,900
Other investments			5,000,000				—				—				5,000,000
Total assets		$	225,890,161			$	151,667,634			$	12,081,298			$	389,639,093
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities:											—
Accounts payable		$	3,424,698			$	1,942,849			$	2,377,362	(B,F)		$	7,744,909
Accrued expenses			3,655,761				3,165,885				—				6,821,646
Debt - current			12,401,279				84,029,298				(31,466,789	)(J)			64,963,788
Finance lease liabilities - current			166,459				—				—				166,459
Operating lease liabilities - current			468,569				124,559				—				593,128
Deferred revenue			882,000				—				—				882,000
Other current liabilities			3,666,092				—				—				3,666,092
Share liability			220,635				—				—				220,635
Due to related parties			3,438,275								—				3,438,275
Total current liabilities			28,323,768				89,262,591				(29,089,427	)			88,496,932
Convertible notes payable, at fair value			97,975,479				—				—				97,975,479
Debt - noncurrent			1,534,686				3,204,250				—				4,738,936
Finance lease liabilities- noncurrent			492,103				—				—				492,103
Operating lease liabilities—noncurrent			617,988				498,066				—				1,116,054
Environmental remediation liability			—				2,636,594				—				2,636,594
Deferred revenue			—				819,154				—				819,154
Deferred tax liability			307,807								—				307,807
Other noncurrent liabilities			34,353				—				—				34,353
Total liabilities			129,286,184				96,420,655				(29,089,427	)			196,617,412
Stockholders’ equity:
Preferred stock			—				—				—				—
Common stock			933,766				—				142,700	(C)			1,076,466
Additional paid-in capital			224,740,838				68,848,906				23,906,094	(D,E)			317,495,838
Accumulated deficit			(152,555,942	)			(20,470,525	)			18,124,331	(G)			(154,902,136	)
Accumulated other comprehensive income (loss)			949,855								277,645	(J)			1,227,500
Share based payment reserve			—				1,240,887				(1,240,887	)(F)			—
Other reserves			—				39,158				39,158	)(G)			—
Total ASP Isotopes/ Renergen stockholders’ equity			74,068,517				49,658,426				41,170,725				164,897,668
Noncontrolling interests			22,535,460				5,588,553				—				28,124,013
Total stockholders’ equity			96,603,977				55,246,979				41,170,725				193,021,681
Total liabilities and stockholders’ equity		$	225,890,161			$	151,667,634			$	12,081,298			$	389,639,093

See accompanying notes to unaudited pro forma condensed combined financial statements.

4

Unaudited Pro Forma Condensed Combined Statement of Operations

		Historical
		ASP Isotopes Inc. Year Ended December 31, 2024				Renergen Year Ended February 28, 2025				ProForma Adjustments Notes (Note3)				Pro Forma
Revenue:
Product revenue		$	3,944,226			$	2,851,330			$	—			$	6,795,556
Collaboration revenue			200,000				—				—				200,000
Total revenue			4,144,226				2,851,330				—				6,995,556
Cost of goods sold			2,544,614				4,386,615				—				6,931,229
Gross profit (loss)			1,599,612				(1,535,285	)			—				64,327
Operating expenses:
Research and development			3,138,978				—				—				3,138,978
Selling, general and administrative			24,814,288				10,767,568				514,924	(B,H)			36,096,780
Total operating expenses			27,953,266				10,767,568				514,924				39,235,758
Loss from operations			(26,353,654	)			(12,302,853	)			(514,924	)			(39,171,431	)
Other income (expenses):
Foreign exchange transaction gain			69,865				(1,983,303	)			—				(1,913,438	)
Other operating income			—				12,420				—				12,420
Change in fair value of share liability			(132,273	)			(170,435	)			—				(302,708	)
Change in fair value of convertible notes payable			(6,875,041	)			—				—				(6,875,041	)
Interest expense			(258,867	)			(4,438,375	)			—				(4,697,242	)
Interest income			1,238,691				590,040				—				1,828,731
Total other expense			(5,957,625	)			(5,989,653	)			—				(11,947,278	)
Loss before income tax			(32,311,279	)			(18,292,506	)			(514,924	)			(51,118,709	)
Income tax benefit (expense)			(111,449	)			2,798,694				—				2,687,245
Net loss before allocation to noncontrolling interests			(32,422,728	)			(15,493,812	)			(514,924	)			(48,431,464	)
Less: Net loss attributable to noncontrolling interests			(89,147	)			(591,353	)			—				(680,500	)
Net loss attributable to ASP Isotopes/Renergen shareholders before deemed dividend from inducement warrant for common stock		$	(32,333,581	)		$	(14,902,459	)		$	(514,924	)		$	(47,750,964	)
Deemed dividend on inducement warrant to purchase common stock			(2,779,659	)			—				—				(2,779,659	)
Net loss attributable to ASP Isotopes/Renergen shareholders		$	(35,113,240	)		$	(14,902,459	)		$	(514,924	)		$	(50,530,623	)
Net loss per common share, basic		$	(0.63	)		$	(0.10	)		$	—			$	(0.72	)
Weighted average shares in issue			55,671,805				148,412,000				—				69,941,805
Comprehensive income (loss):
Net loss before allocation to noncontrolling interests		$	(32,422,728	)		$	(15,493,812	)		$	(514,924	)		$	(48,431,464	)
Foreign currency translation			(1,243,331	)			17,399				—				(1,225,932	)
Total comprehensive loss before allocation to noncontrolling interests		$	(33,666,059	)		$	(15,476,412	)		$	(514,924	)		$	(49,657,396	)
Less: Comprehensive (loss) income attributable to noncontrolling interests			(119,417	)			(591,353	)			—				(710,770	)
Comprehensive loss attributable to ASP Isotopes Inc/Renergen.		$	(33,546,642	)		$	(14,885,059	)		$	(514,924	)		$	(48,946,626	)

See accompanying notes to unaudited pro forma condensed combined financial statements.

5

Unaudited Pro Forma Condensed Combined Statement of Operations

		Historical
		ASP Isotopes Inc. Nine Months Ended September 30, 2025				Renergen Nine Months Ended August 31, 2025				ProForma Adjustments Notes (Note3)				Pro Forma
Revenue:
Product revenue		$	3,570,608			$	2,403,333			$	—			$	5,973,941
Construction services revenue			3,618,868				—				—				3,618,868
Total revenue			7,189,476				2,403,333				—				9,592,809
Cost of goods sold			5,867,360				5,021,244				—				10,888,604
Gross profit (loss)			1,322,116				(2,617,911	)			—				(1,295,795	)
Operating expenses:
Research and development			5,508,227				—				—				5,508,227
Share-based payments expense			—				11,088				(11,088	)(H)			—
Selling, general and administrative			30,701,750				9,255,703				2,345,364	(B),			42,302,817
Total operating expenses			36,209,977				9,266,791				2,334,276				47,811,044
Loss from operations			(34,887,861	)			(11,884,702	)			(2,334,276	)			(49,106,839	)
Other income (expense):
Foreign exchange transaction loss			(140,423	)			—				1,472,565	(I)			1,332,142
Other income			388,847				1,484,531				(1,472,565	)(I)			400,813
Change in fair value of share liability			(200,138	)			—				—				(200,138	)
Change in fair value of convertible notes payable			(64,542,295	)			—				—				(64,542,295	)
Interest expense			(315,010	)			(5,931,153	)			1,189,144	(J)			(5,057,019	)
Interest income			3,282,834				386,009				(1,189,144	)(J)			2,479,699
Total other income (expense)			(61,526,185	)			(4,060,613	)			—				(65,586,798	)
Loss before income tax (expense) benefit			(96,414,046	)			(15,945,315	)			(2,334,276	)			(114,693,637	)
Income tax (expense) benefit			(98,147	)			3,317,359				—				3,219,212
Net loss before allocation to noncontrolling interests			(96,512,193	)			(12,627,956	)			(2,334,276	)			(111,474,425	)
Less: Net (loss) income attributable to noncontrolling interests			129,132				(485,036	)			—				(355,904	)
Net loss attributable to ASP Isotopes/Renergen shareholders		$	(96,383,061	)		$	(12,142,920	)		$	(2,334,276	)		$	(111,830,329	)
Net loss per common share, basic		$	(1.27	)		$	(0.08	)		$	N/A			$	(1.24	)
Weighted average shares in issue			75,985,507				147,591,000				14,270,000				90,255,507
Comprehensive income (loss):
Net loss before allocation to noncontrolling interests		$	(96,512,193	)		$	(12,627,956	)		$	(2,334,276	)		$	(111,474,425	)
Foreign currency translation			3,152,693				4,501				—				3,157,194
Total comprehensive loss before allocation to noncontrolling interests		$	(93,359,500	)		$	(12,623,455	)		$	(2,334,276	)		$	(108,317,231	)
Less: Comprehensive (loss) income attributable to noncontrolling interests			150,929				(485,036	)			—				(334,107	)
Comprehensive loss attributable to ASP Isotopes/Renergen			(93,510,429	)			(12,138,419	)			(2,334,276	)			(107,983,124	)

See accompanying notes to unaudited pro forma condensed combined financial statements.

6

ASP Isotopes Inc.

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED

FINANCIAL STATEMENTS

Year Ended December 31, 2024 and Nine Months Ended September 30, 2025

1. Basis of Presentation

The accompanying unaudited pro forma condensed combined financial statements are based on the historical financial information of ASP Isotopes Inc. (“ASPI” or “the Company”) and Renergen Limited (“Renergen”) after giving effect to the acquisition of Renergen by the Company using the purchase method of accounting and applying the assumptions and adjustments described in the accompanying notes.

The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2025 and for the year ended December 31, 2024 combines the historical results for the Company for each of the periods presented, and the historical results for Renergen for the nine months ended August 31, 2025 and year ended February 28, 2025 as if the acquisition had occurred as of January 1, 2024.

2. Accounting Policy and Reclassification Adjustments

Renergen’s historical financial statements were prepared in accordance with IFRS as issued by the IASB and presented in South African rand. During the preparation of this pro forma financial information, management performed a preliminary analysis of Renergen’s financial information to identify differences between IFRS as issued by IASB and U.S. GAAP, differences in accounting policies compared to those of the Company, and differences in financial statement presentation compared to the presentation of the Company. The conversion of Renergen’s historical financial statements from South African rand (ZAR) to U.S. Dollars using the period-end rate at August 31, 2025 of $0.0567 per ZAR for the unaudited condensed combined pro forma balance sheet and the weighted average of the monthly average rates during the nine months ended August 31, 2025 of $0.0549 per ZAR for the unaudited condensed combined pro forma statement of income. At the time of preparing the unaudited pro forma combined financial information, other than the adjustments described herein, the Company is not aware of any other material differences.

7

Unaudited Pro Forma Condensed Combined Balance Sheet Adjustments

		Renergen Limited August 31, 2025 IFRS ZAR(R)				Presentation (Adjustments and Reclassifications)				Renergen Limited August 31, 2025 Adjusted in US GAAP ZAR(R)				Renergen Limited August 31, 2025 Adjusted in US GAAP USD($)
CURRENT ASSETS:
Cash and cash equivalents		R	163,064,000			R				R	163,064,000			$	9,240,717
Trade and other receivables			34,716,000				(34,716,000	)			-
Accounts receivables			-				(10,341,000	)			10,341,000				586,017
Inventory			989,000								989,000				56,046
Prepaid expenses and other current assets			-				24,375,000				24,375,000				1,381,313
Restricted cash			73,009,000								73,009,000				4,137,367
Lease receivable - current			-				6,968,000				6,968,000				394,871
Finance lease receivables			6,968,000				(6,968,000	)			-				-
Total current assets			278,746,000				-				278,746,000				15,796,331
NON-CURRENT ASSETS:
Property, plant and equipment, net			2,037,978,000				(9,064,000	)			2,028,914,000				114,977,063
Operating lease right-of-use lease assets			-				9,064,000				9,064,000				513,650
Deferred tax assets			186,692,000								186,692,000				10,579,698
Intangible assets			113,570,000								113,570,000				6,435,928
Restricted cash			25,355,000								25,355,000				1,436,849
Lease receivable - noncurrent							34,024,000				34,024,000				1,928,115
Finance lease receivables			34,024,000				(34,024,000	)			-				-
Total assets		R	2,676,365,000			R	-			R	2,676,365,000			$	151,667,635
EQUITY AND LIABILITIES
CURRENT LIABILITIES:
Accounts payable		R	-			R	34,284,000			R	34,284,000			$	1,942,849
Accrued expenses			-				55,866,000				55,866,000				3,165,885
Operating lease liabilities - current			-				2,198,000				2,198,000				124,559
Borrowings / Debt - current			1,482,802,000								1,482,802,000				84,029,298
Trade and other payables			90,150,000				(90,150,000	)			-				-
Lease liabilities			2,198,000				(2,198,000	)							-
Total current liabilities			1,575,150,000				-				1,575,150,000				89,262,591
NON-CURRENT LIABILITIES:
Operating lease liabilities—noncurrent			-				8,789,000				8,789,000				498,066
Borrowings / Debt - noncurrent			56,543,000				-				56,543,000				3,204,250
Lease liabilities			8,789,000				(8,789,000	)			-				-
Deferred revenue			14,455,000								14,455,000				819,154
Provisions			46,526,000								46,526,000				2,636,595
Total liabilities			1,701,463,000				-				1,701,463,000				96,420,656
EQUITY
Stated capital/Additional paid-in capital			1,214,925,000				-				1,214,925,000				68,848,906
Share based payment reserve			21,897,000				-				21,897,000				1,240,887
Other reserves			691,000				-				691,000				39,158
Accumulated (loss)/profit			(361,228,000	)			-				361,228,000	)			(20,470,525	)
Total Renergen stockholders’ equity			876,285,000								876,285,000				49,658,426
Non-controlling interest			98,617,000								98,617,000				5,588,553
Total stockholders’ equity			974,902,000								974,902,000				55,246,979
Total liabilities and stockholders' equity		R	2,676,365,000			R				R	2,676,365,000			$	151,667,635

8

Unaudited Pro Forma Condensed Combined Statement of Operations Adjustments

		Renergen Limited Year Ended February 28, 2025 IFRS ZAR(R)				Renergen Limited Year Ended February 28, 2025 IFRS (USD)				Presentation (Adjustments and Reclassifications)				Renergen Limited Year Ended February 28, 2025 Adjusted in US GAAP USD($)
Product Revenue		$	52,113,000			$	2,851,330			$	-			$	2,851,330
Total Revenue			52,113,000				2,851,330				-				2,851,330
Cost of goods sold			80,173,000				4,386,615				-				4,386,615
Gross profit			(28,060,000	)			(1,535,285	)			-				(1,535,285	)
Operating expenses
Selling, general and administrative			196,796,000				10,767,568				-				10,767,568
Total operating expenses			196,796,000				10,767,568				-				10,767,568
Loss from operations			(224,856,000	)			(12,302,853	)			-				(12,302,853	)
Other income (expenses)
Foreign exchange transaction gain			-				-				(1,983,303	)			(1,983,303	)
Other operating income			227,000				12,420				-				12,420
Change in fair value of share liability			(3,115,000	)			(170,435	)			-				(170,435	)
Change in FV of convertible note payable			-				-				-				-
Interest expense			(81,119,000	)			(4,438,375	)			-				(4,438,375	)
Interest income			10,784,000				590,040				-				590,040
Total other expense			(73,223,000	)			(4,006,350	)			(1,983,303	)			(5,989,653	)
Loss before income tax			(298,079,000	)			(16,309,203	)			(1,983,303	)			(18,292,506	)
Income tax expense			(51,151,000	)			(2,798,694	)			-				(2,798,694	)
Net loss before allocation to noncontrolling interests			(246,928,000	)			(13,510,509	)			(1,983,303	)			(15,493,812	)
Less: Net income (loss) attributable to noncontrolling interests			(10,808,000	)			(591,353	)			-				(591,353	)
Net loss attributable to Renergen shareholders		$	(236,120,000	)		$	(12,919,156	)		$	(1,983,303	)		$	(14,902,459	)
Comprehensive loss
Net loss before allocation to noncontrolling interests		$	(246,928,000	)		$	(13,510,509	)		$	(1,983,303	)		$	(15,493,812	)
Foreign currency translation			318,000				17,399				-				17,399
Total comprehensive loss before allocation to noncontrolling interests			(246,610,000	)			(13,493,110	)			(1,983,303	)			(15,476,413	)
Less: Comprehensive (loss) income attributable to noncontrolling interests			(10,808,000	)			(591,353	)			-				(591,353	)
Comprehensive loss attributable to Renergen.			(235,802,000	)			(12,901,757	)			(1,983,303	)			(14,885,060	)
Loss per share (Basic and diluted)			(1.59	)			(0.09	)			-				(0.10	)